AZTherapies Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Out of Business

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Out of Business

AZTherapies General Information

Description

Operator of a biopharmaceutical company intended to offer treatment for multiple neurodegenerations and neuroinflammation-related central nervous system diseases. The company offers a novel multi-action combination drug regimen that is used to modify disease progression by slowing down or halting Alzheimer's disease early in its development, enabling healthcare providers to easily cure Alzheimer's patients without any surgery.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 200 Clarendon Street
  • 17th Floor
  • Boston, MA 02116
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AZTherapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Out of Business 15-Jan-2024 00000 Completed Out of Business
7. Secondary Transaction - Private 01-Sep-2021 00000 Completed Clinical Trials - Phase 3
6. Later Stage VC (Series C1) 29-Sep-2020 000.00 00000 00000 Completed Clinical Trials - Phase 3
5. Debt - PPP 19-May-2020 000.00 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series C) 31-Jan-2020 000.00 000.00 00000 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series B) 16-Oct-2018 000.00 000.00 00000 Completed Clinical Trials - Phase 3
2. Later Stage VC (Series A) 06-Feb-2017 $16.4M $26.4M 00000 Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 06-Jan-2015 $10M $10M 0000 Completed Clinical Trials - Phase 3
To view AZTherapies’s complete valuation and funding history, request access »

AZTherapies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C1 0,000,000 00.000000 00.00 00.00 00 00.00 00
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-2 0,000,000 00.000000 00.0 00.0 00 00.0 0.000
Series A-1 2,084,052 $0.000100 $3.33 $3.33 1x $3.33 3.52%
Series A 4,212,559 $0.000100 $4 $4 1x $4 7.11%
To view AZTherapies’s complete cap table history, request access »

AZTherapies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to offer treatment for multiple neurodegenerations and neuroinflammatio
Drug Discovery
Boston, MA
12 As of 2023
00000
00000000 00 00000

000 00

te velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cu
0000 000000000
Durham, NC
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00

00000

bore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
Grand Rapids, MI
0 As of 0000
0000
00000 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AZTherapies Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
T3D Therapeutics Venture Capital-Backed Durham, NC 00 000.00 00000000000 000.00
Tetra Therapeutics Formerly VC-backed Grand Rapids, MI 0 0000 000000&0 0000
Cerecin Venture Capital-Backed Singapore, Singapore 00 00000 00000000000 00000
CuraSen Venture Capital-Backed San Carlos, CA 00 000.00 00000000000 000.00
Sangamo Therapeutics Formerly VC-backed Richmond, CA 000 00000 00000000 00000
You’re viewing 5 of 46 competitors. Get the full list »

AZTherapies Patents

AZTherapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4157877-A2 Car-treg-based therapies targeting myelin oligodendrocyte glycoprotein (mog) for treating neurodegenerative diseases Pending 28-May-2020 00000000000
US-20230210899-A1 Car-treg-based therapies targeting myelin oligodendrocyte glycoprotein (mog) for treating neurodegenerative diseases Pending 28-May-2020 000000000
EP-4139458-A1 Cellular ablation of hla-class i mhc Pending 23-Apr-2020 00000000000
US-20230212585-A1 Cellular ablation of hla-class i mhc Pending 23-Apr-2020 00000000000
US-20230065416-A1 Clathrin-chimetic antibody receptor constructs for immune cell activation therapy in vivo Pending 28-Jan-2020 C07K14/7051
To view AZTherapies’s complete patent history, request access »

AZTherapies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AZTherapies Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Smith Therapeutics 24-Oct-2019 0000000000 Biotechnology 00000 000
To view AZTherapies’s complete acquisitions history, request access »

AZTherapies FAQs

  • When was AZTherapies founded?

    AZTherapies was founded in 2011.

  • Who is the founder of AZTherapies?

    David Elmaleh Ph.D is the founder of AZTherapies.

  • Where is AZTherapies headquartered?

    AZTherapies is headquartered in Boston, MA.

  • What is the size of AZTherapies?

    AZTherapies has 12 total employees.

  • What industry is AZTherapies in?

    AZTherapies’s primary industry is Drug Discovery.

  • Is AZTherapies a private or public company?

    AZTherapies is a Private company.

  • What is AZTherapies’s current revenue?

    The current revenue for AZTherapies is 000000.

  • How much funding has AZTherapies raised over time?

    AZTherapies has raised $122M.

  • Who are AZTherapies’s competitors?

    T3D Therapeutics, Tetra Therapeutics, Cerecin, CuraSen, and Sangamo Therapeutics are some of the 46 competitors of AZTherapies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »